Adenosine 5'-Triphosphate (ATP) Challenge in Healthy Non-smokers, Current Smokers and Patients With Mild Asthma and Chronic Obstructive Pulmonary Disease (COPD)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 31
- 试验地点
- 2
- 主要终点
- Lung function
研究概览
简要总结
In this randomised, cross-over, controlled study, a total of 84 subjects will be included: 12 healthy non-smoking volunteers; 12 current smokers; 30 patients with mild steroid-naïve asthma; and 30 patients with mild-moderate COPD.
Each subject will have 1 screening visit (if necessary) and 2 study visits. At visits 2 and 3 the effects of adenosine 5'-triphosphate (ATP) or adenosine 5'-monophosphate (AMP) challenge, given in a random order, will be tested.
详细描述
Background: Extracellular adenosine 5'-triphosphate (ATP) stimulates vagal C and Aδ fibers in the lung, resulting in pronounced bronchoconstriction and cough mediated by P2X2/3 receptors located on vagal sensory nerve terminals. We investigated the effects of nebulized ATP on cough and symptoms in control subjects, healthy smokers, and patients with COPD and compared these responses to the effects of inhaled adenosine, the metabolite of ATP.
Methods: We studied the effects of inhaled ATP and adenosine monophosphate (AMP) on airway caliber, perception of dyspnea assessed by the Borg score, cough sensitivity, and ATP in exhaled breath condensate in healthy nonsmokers (n = 10), healthy smokers (n = 14), and patients with COPD (n = 7).
Results: In comparison with healthy subjects, ATP induced more dyspnea, cough, and throat irritation in smokers and patients with COPD, and the effects of ATP were more pronounced than those of AMP. The concentration of ATP in the exhaled breath condensate of patients with COPD was elevated compared with that of healthy subjects.
Conclusions: Smokers and patients with COPD manifest hypersensitivity to extracellular ATP, which may play a mechanistic role in COPD.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy non-smokers (n=12)
- •Normal spirometry
- •Forced expiratory volume in 1 second (FEV1) reversibility of < 15% after inhaled beta2-agonists*
- •At risk (current smokers) (n=12)*
- •Normal spirometry, chronic symptoms (cough, sputum production)
- •FEV1 reversibility of < 15% after inhaled beta2-agonists* (* = Global Strategy for the Diagnosis, Management, and Prevention of COPD)
- •Mild steroid-naïve asthma (n=30)
- •FEV1 more than or equal to 80%
- •Mild-moderate COPD (n=30)
- •FEV1 50-80%
排除标准
- •Pregnancy, breast-feeding, or planned pregnancy during the study.
- •Fertile women not using acceptable contraceptive measures, as judged by the investigator
- •Upper respiratory infection within the last 4 weeks
- •Subjects who have received research medication within the previous one month
- •Subjects unable to give informed consent
- •Any psychiatric condition rendering the patient unable to understand the nature, scope, and possible consequences of the study.
结局指标
主要结局
Lung function
时间窗: On administration
Spirometry
Borg score
时间窗: On administration
Measurement of DYSPNEA
PC20 of ATP and AMP
时间窗: On administration
PC20 of ATP and AMP
Impulse oscillometry (IOS)
时间窗: On administration
Small airway function
次要结局
未报告次要终点